Market Signal Briefing

Aave [AAVE] breached the $100 support level amid a broader market slip and fell to a three-week low of $96. In fact, at press time, AAVE traded at $97, down 7.7% on the daily charts, while the market cap fell by over $200 million. 

In doing so, the altcoin fell below its short-term Moving Averages (MA), the 9- and 21-day MAs, reflecting strong downside pressure.

AAVE drops below $100  As the crypto market retraced, AAVE market participants turned bearish and began exiting the market aggressively, thereby strengthening downside momentum. 

In fact, the Bulls vs. Bears indicator turned negative after being positive for more than a month. When this metric turns negative, it suggests that sellers have dominated the market and displaced buyers. 

Source: TradingView Furthermore, exchange activities echoed this seller dominance. According to CryptoQuant data, 79k AAVE tokens flowed into exchanges, compared to 74k flowing out. 

Source: CryptoQuant Thus, the altcoin’s Netflow extended its hold within the positive zone for the sixth day, suggesting that sellers have had a strong dominance over the market. 

As a result, the altcoin’s Exchange Supply Ratio jumped to a monthly high of 0.137 as of writing, indicating increased selling activity. Often, such a jump in ESR reduces scarcity, thus increasing the supply available for immediate sale.

Source: CryptoQuant Such a setup on exchanges has preceded strong downward momentum for the asset, leading to lower prices.

What momentum indicators suggest AAVE has experienced strong downward momentum and breached a key support level, with sellers significantly outpacing buyers. Since then, the altcoin’s Relative Strength Index (RSI) dropped deeper into bearish territory, falling to 34 at press time.

With RSI nearing oversold territory, this suggests sellers’ control of the market, while buyers have largely stepped back. Traditionally, such market conditions have strengthened downward momentum, typically resulting in lower prices.

Source: TradingView Therefore, if sellers continue to overrun the market with little resistance, AAVE is likely to slide towards $92 before attempting another leg up.

However, if the market cools down and bulls reclaim $100, the altcoin could set the ground for a rebound. But for a significant trend reversal, bulls need to flip $100 and reclaim the 9- and 21-day MAs at $107 and $110, respectively.

Failure to do so will see the altcoin enter an extended bearish streak, with a likelihood of staying below $100.

Final Summary Aave  dropped 7.7%, breaching $100 and dropping to a three-week low of $96.  AAVE faced intense selling pressure, with bears outpacing bulls, strengthening downside risk.  

Breaking Signal·Market Impact: High

Siren (SIREN) jumped 66.46% to $1.54, leading the 24-hour gainers, according to CoinGecko data. Its market cap sits at $1.12B, ahead of Midnight and Worldcoin on the day’s board. On the downside, Provenance Blockchain (HASH) fell 4.43% to $0.0109 as the session’s biggest decliner by percentage.

Top Gainers Siren (SIREN) rose 66.46% to $1.54. Its market cap is $1.12B, second only to Canton among today’s top five risers. The outsized jump put SIREN well ahead of Midnight and Worldcoin by capitalization on the leaderboard.

Midnight (NIGHT) gained 10.59% to $0.0516. No specific news has been tied to the move. With a market cap of $855.60M, NIGHT sits between SIREN and Worldcoin on today’s leaderboard. The low unit price contrasts with its mid-cap valuation, a reminder that supply, not sticker price, drives market cap.

Canton (CC) rose 9.74% to $0.1537. The project targets enterprise and institutional use cases with an emphasis on regulated finance. Its $5.87B market cap makes it the largest asset among the day’s gainers.

Worldcoin (WLD) added 9.16% to $0.2715. Built by Tools for Humanity, the project pairs a biometric ID system with the WLD token. Traders pointed to broader altcoin rotation. WLD’s market cap stands at $842.64M, narrowly trailing Midnight.

Artificial Superintelligence Alliance (FET) climbed 5.39% to $0.2401. FET is tied to an AI agent and machine-learning infrastructure long associated with Fetch.ai. The token’s market cap is $542.14M. Gains tracked renewed interest in AI-linked tokens.

Top Losers Provenance Blockchain (HASH) fell 4.43% to $0.0109. HASH underpins Provenance, a blockchain used for asset origination, loan servicing, and marketplace rails in traditional finance. Its market cap sits at $614.44M, the largest decline on the day’s losers board by percentage terms. There was no single headline driver during the session.

Beldex (BDX) slipped 2.58% to $0.0807. BDX is a privacy-focused coin with an ecosystem that includes private messaging and transaction tools. Its market cap is $613.81M, almost level with HASH despite the different use cases. Softer prints often coincide with thinner weekend liquidity, though attribution is uncertain.

Filecoin (FIL) eased 2.46% to $0.8074. FIL powers a decentralized storage marketplace that incentivizes miners to provide capacity and retrieval services. Its market cap stands at $616.73M, making it one of the larger assets on the losers list. Trading action remained muted relative to the outsized gains posted at the top of the board.

Stable (STABLE) dropped 2.43% to $0.0254. At $541.37M, its market cap rounds out the day’s bottom-five cohort. Despite the name, STABLE is not trading at a fixed peg. No immediate driver emerged across public channels.

Aptos (APT) declined 2.30% to $0.9361. Aptos is a Layer-1 network built around the Move language by a team with roots in Diem. Its market cap is $743.24M, the largest among today’s decliners. Flows appeared to favor mid-cap gainers over L1s during the session.

Market Outlook Dispersion was wide: the top gainer rose 66.46% while the biggest loser shed 4.43%. Canton’s $5.87B capitalization towered over peers even with a 9.74% advance, while Aptos led decliners by size at $743.24M.

Into quarter-end, watch spot ETF flows, funding conditions, and any rebalancing that could swing liquidity between mid-caps and large-caps. Headlines on protocol upgrades and Bitcoin’s weekly close will help set the tone for the next session.

SourcesCoinGecko

This article was written with AI assistance and reviewed by the The Currency analytics editorial team. Information presented is sourced from publicly available reports. The Currency analytics strives for accuracy but cannot guarantee completeness. This article does not constitute financial advice.

Post Views: 1

Bitcoin entered March on the back of strong momentum, rallying to a high of $76,000 and positioning for its first bullish monthly close in half a year. However, that narrative has since unraveled.

Early optimism, fueled by geopolitical developments involving the U.S, Iran, and Gulf states, has given way to macro-driven caution. At the time of writing, Bitcoin [BTC] was trading near $66,126, holding key levels but showing signs of vulnerability as sentiment shifts.

Bond yields climb, tightening the screws The U.S 10-year Treasury yield has emerged as a central driver of market direction. In fact, the press time price action seemed to suggest that the yield may be consolidating within a bullish flag pattern, typically a precursor to further upside.

A confirmed breakout could push yields towards the 5.0% level or higher, revisiting highs last seen in 2023. Such a move would likely accelerate capital rotation out of risk assets.

Higher yields tend to strengthen the appeal of fixed-income instruments, drawing liquidity away from speculative markets. For Bitcoin, this dynamic has historically translated into downside pressure.

Source: TradingView Between October 2021 and December 2022, for instance, yields rose from 1.45% to 3.90%. All while Bitcoin fell from $67,000 to $16,256 over the same period.

If yields extend towards 5%, Bitcoin could retrace towards its next demand zone between $58,632 and $55,302.

ETF flows flip as U.S investors de-risk Institutional sentiment in the U.S is beginning to turn too. In fact, Spot Bitcoin exchange-traded funds have recorded their first meaningful outflows in five weeks – Signaling a shift towards a risk-off posture.

Roughly $296 million exited these funds over the past week, reversing part of the $2.12 billion accumulated over the previous four weeks. The shift suggested that recent buyers may be beginning to unwind positions as macro risks intensify.

Source: Sosovalue Late-February data reflected this trend best. Between 26-27 February alone, outflows reached approximately $396.7 million, highlighting how quickly sentiment can reverse.

With only a few trading sessions left in March, sustained selling could now cement the bearish monthly close.

Oil surge fuels inflation concerns Here, the inflation backdrop remains a key variable. Crude oil prices have surged sharply, adding pressure to an already fragile macro environment.

Brent crude has already climbed from around $75 at the start of the month to approximately $106, while WTI crude was trading near $101 at press time. The move alluded to supply disruptions and geopolitical tensions, both of which risk sustaining inflation at elevated levels.

Persistently high energy prices limit the likelihood of near-term monetary easing, keeping yields elevated and financial conditions tight.

In fact, recent analysis pointed to oil-driven inflation as a direct headwind for Bitcoin, particularly amid disruptions tied to the Strait of Hormuz. While market analysts argue that Bitcoin could act as a hedge, current price action suggests it remains closely tied to broader liquidity conditions.

Final Summary The U.S 10-year Treasury yield is approaching a breakout, raising the risk of a broader market repricing. U.S investors have begun offloading Bitcoin, as oil-driven inflation continues to complicate the macro outlook.

The cryptocurrency market traded in a mixed range on Sunday, with major assets posting modest gains even as broader activity indicators—particularly in stablecoins, DeFi and derivatives—showed a sharp cooling in 24-hour volumes.

According to TokenPost Market data, Bitcoin (BTC) was changing hands at $66,831, up 1.26% over the previous day as of Sunday UTC. Ethereum (ETH) rose 1.35% to $2,018. The price action suggested cautious risk appetite: spot prices edged higher, but participation metrics hinted at reduced turnover across key trading venues.

Large-cap altcoins also leaned positive. XRP (XRP) gained 1.41%, BNB (BNB) added 1.02%, and Solana (SOL) climbed 0.56%, signaling incremental bid support across the upper tier of the market rather than a broad-based rotation into higher beta tokens.

Total crypto market capitalization stood at approximately $2.31 trillion, while aggregate 24-hour trading volume was about $55.1 billion. Bitcoin’s market dominance ticked up to 57.87%, a 0.01 percentage-point increase from the prior day, while Ethereum’s share also inched higher to 10.54%—another 0.01 percentage-point gain. The small moves in dominance suggest that the day’s advance was largely in line with the market rather than driven by a dramatic shift into or away from majors.

Under the surface, sector-level flows looked less energetic. The DeFi market’s total capitalization was estimated at roughly $58.1 billion, while 24-hour DeFi trading volume fell 34.40% to about $6.11 billion. Stablecoins—often treated as a proxy for on-exchange 'liquidity' and risk transfer—held a combined market capitalization near $288.5 billion, but their 24-hour volume dropped 48.44% to approximately $53.9 billion.

Derivatives activity also retreated. Total 24-hour crypto derivatives volume was reported at around $448.5 billion, down 46.32% from the previous day, indicating that leveraged positioning and short-term hedging demand eased even as spot prices pushed higher.

Overall, the session reflected a market showing modest upside in benchmark tokens alongside slowing transaction intensity—an environment that can point to tentative conviction, with traders watching whether rising prices can be supported by a renewed pickup in 'liquidity inflow' and broader participation.

Article Summary by TokenPost.ai

🔎 Market Interpretation

Prices edged up while activity cooled: Major coins posted modest gains (BTC +$1.26% to $66,831; ETH +$1.35% to $2,018), but key participation indicators weakened across stablecoins, DeFi and derivatives—suggesting the rally was not strongly volume-backed.

Large caps led, not high-beta rotation: XRP (+1.41%), BNB (+1.02%) and SOL (+0.56%) rose slightly, indicating incremental buying in established names rather than a broad speculative shift into smaller alts.

Market structure stayed steady: Total market cap was ~$2.31T with 24h spot volume ~$55.1B. BTC dominance nudged to 57.87% and ETH to 10.54% (both +0.01pp), implying the move was broadly in-line with the market rather than a major redistribution between assets.

Liquidity proxies weakened: Stablecoin 24h volume fell 48.44% to ~$53.9B even as market cap held near $288.5B—a sign of reduced transfer/turnover and potentially less immediate risk-on deployment.

Risk-taking via leverage eased: Derivatives volume dropped 46.32% to ~$448.5B, pointing to cooling leveraged positioning and hedging activity despite higher spot prices.

Net takeaway: A cautious, low-conviction grind higher—prices improved, but the decline in turnover suggests traders are waiting for confirmation via renewed liquidity and broader participation.

💡 Strategic Points

Watch for “confirming volume” before chasing: If BTC/ETH continue rising while stablecoin and derivatives volumes remain depressed, upside may be fragile. Stronger continuation typically comes with rising spot and stablecoin turnover.

Dominance stability favors benchmark-led positioning: With BTC/ETH dominance barely moving, strategies tilted toward majors may align better than aggressive small-cap rotations until breadth and volumes expand.

DeFi cooling may signal reduced risk appetite: DeFi cap (~$58.1B) held, but DeFi volume fell 34.40% to ~$6.11B. If DeFi volumes rebound, it can indicate renewed appetite for on-chain risk and higher-beta exposure.

Derivatives decline reduces squeeze risk but also momentum fuel: Lower derivatives volume can mean fewer crowded leveraged trades (lower squeeze probability), yet it can also mean less near-term momentum from speculative flows.

Key confirmation checklist for the next sessions:

Stablecoin volume re-accelerates (liquidity transfer returns)

Spot volume rises with price (healthier trend)

Derivatives volume/open interest rebuilds without extreme funding (controlled risk-on)

Altcoin breadth improves beyond large caps (broader risk appetite)

📘 Glossary

Market dominance: The share of total crypto market capitalization held by a specific asset (e.g., BTC dominance). Rising dominance can imply relative strength versus the rest of the market.

Stablecoins: Crypto assets designed to track a stable value (often USD). Their trading volume is often used as a proxy for liquidity and capital rotation within crypto markets.

DeFi (Decentralized Finance): On-chain financial applications (lending, trading, derivatives, etc.) that operate without traditional intermediaries.

Derivatives volume: Trading activity in futures/options/perpetual swaps. Often reflects leveraged positioning and short-term hedging/speculation.

Spot price: The current market price for immediate settlement (non-derivatives).

Risk appetite: The willingness of investors to take on risk; typically higher when capital rotates into more volatile assets and leverage increases.

Liquidity inflow: A practical shorthand for increased deployable capital and turnover entering the market—often observed via higher stablecoin transfer/trading activity and rising spot volumes.

<Copyright ⓒ TokenPost, unauthorized reproduction and redistribution prohibited>

3.71K Followers

Analyst’s Disclosure: I/we have a beneficial long position in the shares of NGS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

LOS ANGELES--(BUSINESS WIRE)---- $IBRX--IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm.

Boston Scientific Corporation (BSX) American College of Cardiology 75th Annual Scientific Session and Expo March 28, 2026 6:30 PM EDT

Company Participants

Lauren Tengler - Director of Investor Relations
Ken Stein - Senior VP & Global Chief Medical Officer
Michael Jaff
Brad Sutton
Martin Leon

Conference Call Participants

Shagun Singh Chadha - RBC Capital Markets, Research Division
Matthew Miksic - Barclays Bank PLC, Research Division
David Roman - Goldman Sachs Group, Inc., Research Division
Christopher Pasquale - Nephron Research LLC
Joshua Jennings - TD Cowen, Research Division
Joanne Wuensch - Citigroup Inc., Research Division
Pito Chickering - Deutsche Bank AG, Research Division
Larry Biegelsen - Wells Fargo Securities, LLC, Research Division
Anthony Petrone - Mizuho Securities USA LLC, Research Division

Presentation

Operator

Good evening, and welcome to the Boston Scientific American College of Cardiology Conference Call.

[Operator Instructions]

Please note, this event is being recorded.

I would now like to turn the conference over to Lauren Tengler, Vice President, Investor Relations. Please go ahead.

Lauren Tengler
Director of Investor Relations

Thanks, Drew. Thanks to everyone for joining us. With me to discuss our CHAMPION-AF and HI-PEITHO trials are Dr. Ken Stein, our Chief Medical Officer; Dr. Michael Jaff, Chief Medical Officer, Vascular Therapies; and Dr. Brad Sutton, Chief Medical Officer, AF Solutions.

During the Q&A session, Dr. Stein, Dr. Jaff and Dr. Sutton will be joined by Dr. Marty Leon, Study Co-Chair, Mallah Professor of Cardiology, Chief Innovation Officer and Director, Cardiovascular Data Science Center, Columbia University Medical Center.

We issued 2 press releases earlier today of the data presentation of each HI-PEITHO and CHAMPION-AF clinical trials. The releases can be found on the Investor Relations section of our website.

This call contains forward-looking statements regarding, among other things, our financial performance, business plans, clinical trials and product performance and development. These statements are based on our current beliefs using information available to us as

New York, New York--(Newsfile Corp. - March 28, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of TruBridge, Inc. (NASDAQ: TBRG) resulting from allegations that TruBridge may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased TruBridge securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=56548 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

WHAT IS THIS ABOUT: On March 17, 2026, TruBridge filed a Notification of Late Filing on Form 12b-25, in which it stated that TruBridge was unable to file its Annual Report for the fiscal year ended December 31, 2025. The report stated its inability to file was a result of "the identification of out-of-period errors of previously issued financial statements and the consequential need to complete certain related analyses." In addition, the report stated that "the Company's management identified errors in the Company's previously issued consolidated financial statements, including for the years ended December 31, 2024 and December 31, 2023, as well as out-of-period errors in the condensed financial statements for the quarters ended March 31, June 30, and September 30, 2025. These errors relate to revenue recognition and related contract cost, stock-based compensation expense, and capitalized software development expense. As a result, the Company is required to make revisions to its previously issued consolidated financial statements for the years ended December 31, 2024 and December 31, 2023, filed with its Annual Reports on Form 10-K for the years then ended, in order to recognize certain of such revenues, costs and expenses in the appropriate fiscal year."

On this news, TruBridge's stock price fell $1.84 per share, or 10.5%, to close at $15.75 per share on March 17, 2026.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/290354

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

New York, New York--(Newsfile Corp. - March 28, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between October 10, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 7, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Inovio securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Inovio class action, go to https://rosenlegal.com/submit-form/?case_id=52847 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 7, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) manufacturing for Inovio's CELLECTRA device was deficient; (2) accordingly, Inovio was unlikely to submit the INO-3107 Biologics License Application ("BLA") to the U.S. Food and Drug Administration ("FDA") by the second half of 2024; (3) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (4) accordingly, INO-3107's overall regulatory and commercial prospects were overstated; and (5) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Inovio class action, go to https://rosenlegal.com/submit-form/?case_id=52847 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/290356

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

NEW YORK, March 28, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Navan, Inc. (NASDAQ: NAVN) pursuant and/or traceable to the Registration Statement and Prospectus (collectively, the “Offering Documents”) issued in connection with Navan’s October 2025 initial public offering (the “IPO”), of the important April 24, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Navan common stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Navan class action, go to https://rosenlegal.com/submit-form/?case_id=55059 or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 24, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, the Offering Documents used to effectuate Navan’s IPO were false and misleading and omitted to state that, at the time of the offering, Navan had increased its “sales and marketing” expenses. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Navan class action, go to https://rosenlegal.com/submit-form/?case_id=55059 or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

New York, New York--(Newsfile Corp. - March 28, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased Disc Medicine securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=56641 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

WHAT IS THIS ABOUT: On February 13, 2026, the U.S. Food and Drug Administration ("FDA") issued a Complete Response Letter ("CRL") to Disc Medicine regarding its bitopertin program. The FDA stated they could not approve Disc Medicine's new drug application ("NDA") as there were uncertainties in the NDA that would need additional evidence.

On this news, Disc Medicine's stock price fell 22% on February 13, 2026.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/290359

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

NEW YORK, March 28, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) resulting from allegations that Aldeyra may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased Aldeyra securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=38697 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

WHAT IS THIS ABOUT: On March 17 2026, Aldeyra filed with the Securities and Exchange Commission a Current Report on Form 8-K, in which it announced its receipt from the U.S. Food and Drug Administration (“FDA”) a Complete Response Letter (“CRL”) regarding its New Drug Application (“NDA”) of reproxalap. The report stated that the “CRL stated that there is “a lack of substantial evidence consisting of adequate and well-controlled investigations … that the drug product will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in its proposed labeling” and that “the application has failed to demonstrate efficacy in adequate and well controlled studies in the treatment of signs and symptoms of dry eye disease.” The letter also stated that the “inconsistency of study results raises serious concerns about the reliability and meaningfulness of the positive findings” and that the “totality of evidence from the completed clinical trials does not support the effectiveness of the product.””

On this news, Aldeyra’s stock price fell $2.99 per share, or 70.7% to close at $1.24 per share on March 17, 2026.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

HomeETFs and Funds AnalysisClosed End Funds Analysis

SummaryAberdeen infrastructure CEF ASGI proposes removing its 2035 term structure, a move that is detrimental to shareholder interests and alpha opportunities.Loan CEFs have cheapened as anticipated, following distribution cuts following Fed policy rate expectations.CLO Equity CEFs like OCCI, CCIF, EARN, and SPMC reported significant February NAV declines, raising leverage, leading to potential forced asset sales in a fragile sector.BlackRock loan CEFs BSL, BGX, and BGB adjusted distributions.I do much more than just articles at Systematic Income: Members get access to model portfolios, regular updates, a chat room, and more. Learn More » bymuratdeniz/iStock via Getty Images

Welcome to another installment of our CEF Market Weekly Review, where we discuss closed-end fund [CEF] market activity from both the bottom-up - highlighting individual fund news and events - as well as the top-down - providing an overview of the broader market. We also

13.67K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Fastly, Inc. is rated Buy, driven by robust revenue growth, improving profitability, and strong management and analyst guidance. Management forecasts 2026 revenue of $700–$720 million and Non-GAAP EPS of $0.23–$0.29, implying a 100% earnings increase. Operational, legal, and short-interest risks remain material, including customer concentration, outages, and high capital intensity versus larger competitors.

LOS ANGELES--(BUSINESS WIRE)---- $WMK--WMK Investors Have Opportunity to Join Weis Markets, Inc. Fraud Investigation with the Schall Law Firm.

New York, New York--(Newsfile Corp. - March 28, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, 2026, inclusive (the "Class Period"), of the important April 14, 2026 lead plaintiff deadline.

SO WHAT: If you purchased REGENXBIO securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the REGENXBIO class action, go to https://rosenlegal.com/submit-form/?case_id=53421 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 14, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants provided investors with material information concerning REGENXBIO's plan to develop and commercialize its product candidate RGX-111, a one-time gene therapy for the treatment of severe Mucopolysaccharidosis Type I, also known as Hurler syndrome. Defendants' statements included, among other things, REGENXBIO's positive assertions of RGX-111's future trial success based on continuing positive biomarker and safety data from the ongoing PhaseI/II study. Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning the efficacy and safety of its RGX-111 trial study. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the REGENXBIO class action, go to https://rosenlegal.com/submit-form/?case_id=53421 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/290348

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

New York, New York--(Newsfile Corp. - March 28, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Shares ("ADS") of Mereo BioPharma Group plc (NASDAQ: MREO) between June 5, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Mereo ADSs during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Mereo class action, go to https://rosenlegal.com/submit-form/?case_id=52452 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 6, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants provided investors with material information concerning their expected results for the Phase 3 Orbit and COSMIC studies for setrusumab in Osteogenesis Imperfecta (OI). Defendants' statements included, among other things, confidence in setrusumab's ability to ultimately reduce the annualized fracture rates of the tested patients and in the study itself to put setrusumab in an opportunity to succeed in reaching statistical significance of this key endpoint.

The defendants, the lawsuit claims, provided these positive statements to investors while, at the same time, disseminating false and materially misleading statements and/or concealing material adverse facts concerning the true state of the Phase 3 ORBIT and COSMIC programs; neither of which hit their primary endpoints of reducing annualized clinical fracture rate compared to the placebo or bisphosphonate control groups, respectively. Such statements absent these material facts caused investors to purchase Mereo's ADSs at artificially inflated prices. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Mereo class action, go to https://rosenlegal.com/submit-form/?case_id=52452 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/290346

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

1.62K Followers

Analyst’s Disclosure: I/we have a beneficial long position in the shares of VONOY either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

NEW YORK, March 28, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025 and October 31, 2025, inclusive (the “Class Period”), of the important April 13, 2026 lead plaintiff deadline.

SO WHAT: If you purchased uniQure ordinary shares during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the uniQure class action, go to https://rosenlegal.com/submit-form/?case_id=53025 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 13, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants misrepresented and/or failed to disclose that: (1) the design of uniQure’s Pivotal Study (a study of uniQure’s leading drug candidate in patients with Huntington’s Disease) — including comparison of the Pivotal Study results to the ENROLL-HD external historical data set— was not fully approved by the U.S. Food and Drug Administration (the “FDA”); (2) defendants downplayed the likelihood that, despite purportedly highly successful results from the Pivotal Study, uniQure would have to delay its Biologics License Application (“BLA”) timeline to perform additional studies to supplement its BLA submission; and (3) as a result, defendants’ statements about uniQure’s business, operations, and prospects lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the uniQure class action, go to https://rosenlegal.com/submit-form/?case_id=53025 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

New York, New York--(Newsfile Corp. - March 28, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Trip.com Group Limited (NASDAQ: TCOM) between April 30, 2024 and January 13, 2026, both dates inclusive (the "Class Period"), of the important May 11, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.

SO WHAT: If you purchased Trip.com securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Trip.com class action, go to https://rosenlegal.com/submit-form/?case_id=50668 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 11, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) defendants recklessly understated the regulatory risk facing Trip.com as a result of its monopolistic business activities; and (2) as a result, defendants' statements about Trip.com's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Trip.com class action, go to https://rosenlegal.com/submit-form/?case_id=50668 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/290352

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

New York, New York--(Newsfile Corp. - March 28, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Richtech Robotics Inc. (NASDAQ: RR) between January 27, 2026 and 12:00 PM ET on January 29, 2026, both dates inclusive (the "Class Period"), of the important April 3, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.

SO WHAT: If you purchased Richtech securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Richtech class action, go to https://rosenlegal.com/submit-form/?case_id=51742 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 3, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Richtech claimed that it had a collaborative and commercial relationship with Microsoft when it did not; and (2) as a result, defendants' statements about Richtech's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Richtech class action, go to https://rosenlegal.com/submit-form/?case_id=51742 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/290235

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

LOS ANGELES--(BUSINESS WIRE)---- $EVTL--EVTL Investors Have Opportunity to Join Vertical Aerospace Ltd. Fraud Investigation with the Schall Law Firm.

NEW YORK, March 28, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GSI Technology Inc. (NASDAQ: GSIT) resulting from allegations that GSI Technology may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased GSI Technology securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=52527 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

WHAT IS THIS ABOUT: On February 3, 2026, a post was issued on Stockwits in which it stated that “GSI is almost certainly hiding that their chip did not run Gemma-3 at all, only the pre-generation RAG phase. APU lack the MAC units required for matrix multiplication, which is critical for AI workloads.”

On this news, GSI Technology’s stock price fell $1.08 per share, or 14.2%, to close at $6.52 per share on February 4, 2026.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

, /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of  securities of Hercules Capital, Inc. (NYSE: HTGC) between May 1, 2025 and February 27, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 19, 2026.

So what: If you purchased Hercules Capital securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Hercules Capital class action, go to https://rosenlegal.com/submit-form/?case_id=56968 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 19, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Hercules Capital overstated the due diligence with which it conducted its deal sourcing and/or loan origination process; (2) Hercules Capital overstated the due diligence with which it conducted its portfolio valuation process; (3) Hercules Capital reported misclassified portfolio investments; (4) as a result of the foregoing, Hercules Capital overstated and/or misrepresented its portfolio valuations; and (5) as a result of the foregoing, defendants' positive statements about Hercules Capital's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages. 

To join the Hercules Capital class action, go to https://rosenlegal.com/submit-form/?case_id=56968 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

     Laurence Rosen, Esq.
     Phillip Kim, Esq.
     The Rosen Law Firm, P.A.
     275 Madison Avenue, 40th Floor
     New York, NY 10016
     Tel: (212) 686-1060
     Toll Free: (866) 767-3653
     Fax: (212) 202-3827
     [email protected]
     www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

📊
No votes yet – Be the first to vote

Dogecoin’s fighting for survival. The meme coin dropped over 23% since January but still trades above the critical $0.060 support level that traders watch like hawks during Tuesday’s Asian session.

The popular dog-themed cryptocurrency changed hands at $0.065 on Tuesday morning, way down from its $0.085 starting point when 2026 kicked off. But here’s the thing – it’s still holding above that make-or-break $0.060 threshold that pretty much everyone in the crypto space considers crucial. Break below that level and things could get ugly fast. For now though, Dogecoin’s managing to stay afloat while the broader crypto market gets hammered by a perfect storm of economic headwinds and regulatory fears.

Trading volumes tell the story. Daily volume crashed to $300 million on March 27, down from $500 million at year’s start.

Market Forces Hit Hard Several factors crushed Dogecoin’s momentum over the past few months. Rising interest rates and inflation worries spooked investors away from risky assets like crypto. And let’s be honest – when the Federal Reserve keeps hiking rates, people don’t want to park money in volatile digital coins that can swing 20% in a day. Regulatory crackdowns on major exchanges didn’t help either, with traders getting nervous about potential government interference.

But there’s something else missing from the equation. Elon Musk’s Twitter cheerleading, which used to send Dogecoin to the moon with a single tweet, has been basically nonexistent lately. Without those celebrity endorsements pumping up the hype, Dogecoin’s been left to sink or swim based on actual market fundamentals. Not exactly its strong suit.

The technical picture looks rough too. Sarah Tran from FXStreet noted on March 27 that Dogecoin’s Relative Strength Index hit oversold territory. She thinks that might create a buying opportunity if the $0.060 support holds, but that’s a big if right now.

Analysts can’t agree on what comes next.

Mixed Signals From Key Players Tom Lee from Fundstrat Global Advisors weighed in on March 25, calling Dogecoin’s ability to stay above $0.060 “a positive sign” for recovery if broader market conditions improve. But he’s been wrong before, and market conditions aren’t exactly improving at the moment. Global economic uncertainty keeps weighing on risk assets across the board.

Binance threw Dogecoin a small bone on March 20 by adding a new DOGE/USDT trading pair. The exchange said it wanted to give traders more flexibility managing their Dogecoin positions. Whether that actually helps boost trading activity remains unclear – volume’s still way down from earlier this year. Industry observers have noted parallels with Crypto Stablecoin Bill Hits Wall as in recent weeks.

Robinhood’s massive Dogecoin stash keeps hanging over the market like a sword. The trading platform reportedly holds about 24% of all Dogecoin in circulation as of March 26. That’s a huge concentration of coins in one place, and any major moves by Robinhood could seriously impact prices. They haven’t said anything about their plans lately.

The Dogecoin Foundation hasn’t released any major updates recently but stays active on social media trying to keep the community engaged. Hard to maintain investor confidence when prices keep sliding though. Community enthusiasm only goes so far when people are losing money.

What’s Next for DOGE Tesla’s Dogecoin integration for merchandise purchases earlier this year generated some buzz but hasn’t moved the needle much on price. Musk’s broader strategy to promote crypto payments sounds good in theory, but the real-world impact has been pretty limited so far. Maybe that changes if more companies follow Tesla’s lead, but don’t hold your breath.

Mining activity picked up slightly on March 22 with a modest hash rate increase. Miners seem a bit more confident, which could signal some underlying strength in the network. Then again, it might just be temporary noise in the data.

Grayscale Investments mentioned in a March 24 report that Dogecoin still ranks in the top ten cryptocurrencies by market cap. The asset manager highlighted both Dogecoin’s volatility potential and its resilience in maintaining market presence. That’s about as lukewarm an endorsement as you can get from institutional investors.

The upcoming DogeCon conference on April 15 might shake things up. Industry insiders think announcements from that event could influence Dogecoin’s direction, but nobody knows what to expect. Key crypto figures are scheduled to speak, potentially setting up new developments or partnerships that could impact prices. Analysts have drawn connections to UK Hits Xinbi Platform With Sanctions amid evolving conditions.

For now, all eyes stay glued to that $0.060 support level. Traders know a break below could trigger more selling pressure and send Dogecoin spiraling lower. The crypto market’s been brutal this year, and Dogecoin’s just trying to survive the storm like everyone else.

Several major crypto exchanges have quietly reduced their Dogecoin marketing efforts compared to 2025’s aggressive promotional campaigns. Coinbase removed Dogecoin from its featured assets list on March 23, while Kraken cut its DOGE staking rewards by 40% earlier this month. These moves reflect broader institutional skepticism about meme coins during the current market downturn.

Whale activity patterns show mixed signals too. Blockchain analytics firm Santiment reported on March 26 that addresses holding over 1 million DOGE decreased by 3.2% in the past month, suggesting some large holders are quietly exiting positions. However, retail accumulation picked up slightly with smaller wallets adding modest amounts during recent price dips. The divergence between institutional and retail behavior creates an interesting dynamic that could influence Dogecoin’s next major price movement.

Frequently Asked QuestionsWhy did Dogecoin drop 23% this year?Rising interest rates, inflation concerns, and regulatory scrutiny on crypto exchanges created selling pressure across the entire cryptocurrency market, hitting Dogecoin particularly hard.

What happens if Dogecoin breaks below $0.060?Traders consider $0.060 a critical support level – a break below could trigger additional selling and send prices significantly lower in the near term.

Post Views: 1